ReviewBioMed research international2013
18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma.
Review in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Pooled it
- Article
- Prognostic Value of 18 F-FDG PET in Primary Central Nervous System Lymphoma : Assessing Interim Metabolic Response for Improving Patient Stratification.Clinical nuclear medicine · 2025Article
- Inflammatory and immunopathological differences in brains of permissive and non-permissive hosts with Angiostrongylus cantonensis infection can be identified using 18F/FDG/PET-imaging.PLoS neglected tropical diseases · 2024Article
- Differential Diagnosis of Tumor-like Brain Lesions.Neurology. Clinical practice · 2023Review
- Theranostics in Hematooncology.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Improving the Classification of PCNSL and Brain Metastases by Developing a Machine Learning Model Based onJournal of personalized medicine · 2023Article
- Lymphomatosis cerebri: a rare diffuse leukoencephalopathy you should never miss.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Unleashing the Mystery of a Treated Case of Medulloblastoma.The Indian journal of radiology & imaging · 2022Article
- Review
- Usefulness of dual isotopeInternational journal of clinical oncology · 2022Article
- Review
- Differentiating between Primary Central Nervous System Lymphoma and Glioblastoma: The Diagnostic Value of CombiningNeurologia medico-chirurgica · 2021Article
- Use of FDG-PET/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study.Journal of neuro-oncology · 2020Article
- Neuroradiological features of lymphomatosis cerebri: A systematic review of the English literature with a new case report.Oncology letters · 2018Article
- Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients.Oncotarget · 2018Article
- 18F-FDG PET/CT in primary brain lymphoma.Journal of neuro-oncology · 2018Article
- Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring.BioMed research international · 2018Review
- Article
- Case-based review: primary central nervous system lymphoma.Neuro-oncology practice · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper summarizes the usefulness and limitation of positron emission tomography (PET) with (18)F-fluorodeoxyglucose ((18)F-FDG) in the diagnosis and treatment of primary central nervous system lymphoma (PCNSL). The (18)F-FDG uptake in typical PCNSL is about 2.5 times higher than that in the normal gray matter, and the tumor can usually be identified visually. The (18)F-FDG uptake pattern and value provide useful information for differentiating PCNSL from other enhancing malignant brain tumors especially glioblastoma (GB). The (18)F-FDG uptake in typical PCNSL is usually homogenous, and the uptake value is significantly higher than that in GB. However, (18)F-FDG PET often fails to show the presence of tumor in the brain as (18)F-FDG uptake is faint in atypical PCNSL such as disseminated or nonenhancing lesions. (18)F-FDG PET is also useful for evaluating the treatment response at a very early stage after the initial treatment. Pretreatment and posttreatment (18)F-FDG uptake values may have a prognostic value in patients with PCNSL. In conclusion, (18)F-FDG PET is very useful in the diagnosis of typical PCNSL and can differentiate PCNSL from other malignant brain tumors. However, the usefulness of (18)F-FDG PET is limited in the diagnosis of atypical PCNSL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.